Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | AKT2 | P31751 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 18/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20544744 | 0.86 | ROCK2 (0.46) | ROCK2AKT1UTS2R | |
| SCHEMBL20544787 | 0.82 | UTS2R (0.49) | UTS2R | |
| SCHEMBL390933 | 0.82 | P2RY2 (0.44) | ROCK2AKT1AKT2KCNH2AKT3 | |
| SCHEMBL391960 | 0.80 | MTNR1A (0.50) | AKT1UTS2R | |
| SCHEMBL20544982 | 0.77 | WDR91 (0.49) | UTS2R | |
| SCHEMBL20544852 | 0.77 | ROCK2 (0.46) | ROCK2AKT1UTS2R | |
| SCHEMBL20544753 | 0.77 | THRB (0.48) | AKT1UTS2R | |
| SCHEMBL20544752 | 0.76 | UTS2R (0.48) | UTS2R | |
| SCHEMBL20544814 | 0.75 | GABBR2 (0.44) | ROCK2AKT1UTS2R | |
| SCHEMBL390688 | 0.75 | KIF11 (0.41) | ROCK2AKT1AKT2KCNH2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | PRKAR2B, PRKCB, AKT1 | ROCK2 60/4885AKT1 3/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.